Zhen Zeng, Ph.D., is a Principal on the Public Structured Finance team. He joined the Firm in 2021 working as a Biostatistician on the Therapeutics team. Prior to Deerfield, Dr. Zeng spent over two years as Vice President of Biotechnology Equity Research at Morgan Stanley. Before Morgan Stanley, he worked as a Senior Scientist at Merck for more than three years. Dr. Zeng holds a B.E. in Bioengineering from the Harbin Institute of Technology, an M.S. in Biochemistry and Molecular Biology from Shanghai Jiao Tong University, an M.S. in Human Genetics from the University of Pittsburgh and a Ph.D. in Biostatistics from the University of Pittsburgh.
Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.
Read More
Investment
Supporting companies across the healthcare ecosystem with flexible funding models…
Read MoreFeatured
Deerfield Management and the University of North Carolina Eshelman School of Pharmacy Launch Biotherapeutics Certificate Program Bridging Academia and Industry Deerfield Management Launches Joint Venture with Horizon Blue Cross Blue Shield of New Jersey Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund
Portfolio Companies
Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.
Read More View Portfolio Companies
Research Collaborations
Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.
Read More View Research Collaborations
Strategic Partners
As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.
Read More
Deerfield Foundation
The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.
Read More Meet the Foundation TeamFoundation Partners by Focus
Children's Health Diversity Initiatives Maternal Health View AllFounded Diversity Programs
Break into the Boardroom Fellowships Science to the Street (formerly Women in Science)
Cure Campus
Cure is a 12-story innovation campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.
Read More Join the Cure Email ListCure Programming
Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.
Events at the Cure
Elise Wang
Elise Wang is a Partner and Head of Private Equity Capital Markets on the Public Structured Finance team and joined the Firm in 2010. Ms. Wang provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe. Ms. Wang is a board member of Jaguar Gene Therapy. Prior to Deerfield, Ms. Wang was a Senior Research Analyst and Managing Director covering the biotechnology sector at PaineWebber and Citigroup. She began her career in healthcare as a venture capitalist and banker at PaineWebber and was an officer of PaineWebber Development Corporation, which managed nearly $1 billion in assets representing three PaineWebber funds and several research and development limited partnerships (RDLPs) invested in biotechnology and high technology companies. Ms. Wang holds an A.B. in Engineering Sciences with a specialty in Biomechanics from Harvard University and an M.B.A. from Harvard Business School.
